<DOC>
	<DOCNO>NCT00910728</DOCNO>
	<brief_summary>This study conduct test study drug AZD1480 see may work treat myeloproliferative disease . The main purpose study determine safety tolerability AZD1480 . This first time drug give human class first time man study . Its main purpose establish safe dosage drug provide additional information potential side effect drug may cause . The study also assess blood level action AZD1480 body period time indicate whether drug therapeutic effect myeloproliferative disease .</brief_summary>
	<brief_title>Study Assess Safety AZD1480 Patients With Myeloproliferative Diseases</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Patients myelofibrosis require therapy Evidence postmenopausal status sterile ECOG Performance Status &lt; /=2 Prior therapy JAK2 medication Significant lung disorder lung disease Previous radiation therapy chest wall chest infection require antibiotic treatment within 28 day study screen Eye disease cornea Patients require oxygen supplementation Ejection fraction &lt; 45 % ( ECHO/MUGA ) significant pulmonary hypertension &gt; 40 mm Hg ( Echo/Doppler ) Forced Expiratory Volume ( FEV1 ) /Forced Vital Capacity ( FVC ) &lt; 70 % predict &gt; 130 % predict Diffusing capacity Lung Carbon Monoxide ( DLCO ) correct hemoglobin &lt; 60 % predict , oxygen saturation &lt; 88 % rest 6minute flat walk , without supplemental oxygen Chest infection require antibiotic within 7 day first dose Investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Primary Myelofibrosis ( PMF )</keyword>
	<keyword>Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis ( Post-PV/ET MF )</keyword>
	<keyword>Myeloproliferative disease</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
	<keyword>Bone marrow</keyword>
</DOC>